SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 29, 2005
CERUS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware |
|
0-21937 |
|
68-0262011 |
(State of jurisdiction) |
|
(Commission File No.) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
2411 Stanwell Drive |
||||
(Address of principal executive offices and zip code) |
||||
|
|
|
|
|
Registrants telephone number, including area code: (925) 288-6000 |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On November 29, 2005, Cerus Corporation (the Company) received a $2.0 million payment from BioOne Corporation (BioOne) as partial consideration for the license and related rights granted to BioOne pursuant to that certain Commercialization Agreement, dated as of May 27, 2005, by and among the Company, BioOne and subsidiaries of Baxter International Inc. (the Agreement). The $2.0 million payment will be recognized by the Company over the remaining development period.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CERUS CORPORATION |
|
|
|
|
|
|
|
Dated: November 30, 2005 |
By: |
/s/ Howard G. Ervin |
|
|
Howard G. Ervin |
|
|
Vice President, Legal Affairs |
3